Bartłomiej Sankowski1, Karolina Księżarczyk1, Emilia Raćkowska1, Stanisław Szlufik2, Dariusz Koziorowski2, Joanna Giebułtowicz3. 1. Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw 02-097, Poland. 2. Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, 8 Kondratowicza Street, Warsaw 03-242, Poland. 3. Department of Bioanalysis and Drug Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw 02-097, Poland. Electronic address: joanna.giebultowicz@wum.edu.pl.
Abstract
BACKGROUND: In Parkinson's disease (PD), impairment of brain to blood barrier and/or blood-cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentrations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. METHODS: Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. RESULTS: In PD, for IS and pCS, CSF-plasma ratio was higher. Concentration of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. CONCLUSIONS: The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
BACKGROUND: In Parkinson's disease (PD), impairment of brain to blood barrier and/or blood-cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentrations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. METHODS: Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. RESULTS: In PD, for IS and pCS, CSF-plasma ratio was higher. Concentration of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. CONCLUSIONS: The level of pCS and IS in CSF of PDis higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
Authors: Brittany D Needham; Masanori Funabashi; Mark D Adame; Zhuo Wang; Joseph C Boktor; Jillian Haney; Wei-Li Wu; Claire Rabut; Mark S Ladinsky; Son-Jong Hwang; Yumei Guo; Qiyun Zhu; Jessica A Griffiths; Rob Knight; Pamela J Bjorkman; Mikhail G Shapiro; Daniel H Geschwind; Daniel P Holschneider; Michael A Fischbach; Sarkis K Mazmanian Journal: Nature Date: 2022-02-14 Impact factor: 69.504
Authors: Sophie Liabeuf; Marion Pepin; Casper F M Franssen; Davide Viggiano; Sol Carriazo; Ron T Gansevoort; Loreto Gesualdo; Gaye Hafez; Jolanta Malyszko; Christopher Mayer; Dorothea Nitsch; Alberto Ortiz; Vesna Pešić; Andrzej Wiecek; Ziad A Massy Journal: Nephrol Dial Transplant Date: 2021-12-28 Impact factor: 5.992
Authors: Kathryn C Fitzgerald; Matthew D Smith; Sol Kim; Elias S Sotirchos; Michael D Kornberg; Morgan Douglas; Bardia Nourbakhsh; Jennifer Graves; Ramandeep Rattan; Laila Poisson; Mirela Cerghet; Ellen M Mowry; Emmanuelle Waubant; Shailendra Giri; Peter A Calabresi; Pavan Bhargava Journal: Cell Rep Med Date: 2021-10-19